Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.
Brendan M. Everett,Aruna D. Pradhan,Aruna D. Pradhan,Daniel H. Solomon,Nina P. Paynter,Jean G. MacFadyen,Elaine Zaharris,Milan Gupta,Michael Clearfield,Peter Libby,Ahmed A. K. Hasan,Robert J. Glynn,Paul M. Ridker +12 more
Reads0
Chats0
TLDR
If low-dose methotrexate reduces cardiovascular events, CIRT would provide a novel therapeutic approach for the secondary prevention of heart attack, stroke, and cardiovascular death.About:
This article is published in American Heart Journal.The article was published on 2013-08-01 and is currently open access. It has received 347 citations till now. The article focuses on the topics: Myocardial infarction & Rheumatoid arthritis.read more
Citations
More filters
Journal ArticleDOI
Involvement of Inflammation and Its Resolution in Disease and Therapeutics
Sebastián Rodríguez Alfaro,Vania Acuña,Ricardo Ceriani,María Fernanda Cavieres,Caroline Weinstein-Oppenheimer,Carolina Campos-Estrada +5 more
TL;DR: It is concluded that resolution pharmacology and advanced therapies are promising tools to restore the inflammation homeostasis.
Journal ArticleDOI
Preventing Heart Failure in Inflammatory and Immune Disorders.
Maya Serhal,Chris T. Longenecker +1 more
TL;DR: It is proposed how a strategy for heart failure prevention, such as the model tested in the Screening To Prevent Heart Failure (STOP-HF) trial, may be adapted to chronic inflammatory disease.
Journal ArticleDOI
Fine-tuning inflammation-resolution programs: focus on atherosclerosis.
TL;DR: Recent work that supports the concept of dysregulated inflammation-resolution in atherosclerosis is highlighted with a particular focus on mechanisms and therapeutic opportunities associated with SPM receptors and lipid mediator imbalances.
Journal ArticleDOI
Role of herpesviruses in coronary artery disease
Agam Bansal,Debasis Biswas +1 more
TL;DR: The association between HSV infection and atherosclerosis is not related to its seroprevalence, and the association in developing countries and developed countries is no significant association.
References
More filters
Journal ArticleDOI
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein,Michael Miller,Robert P. Byington,David C. Goff,J. Thomas Bigger,John B. Buse,William C. Cushman,Saul Genuth,Faramarz Ismail-Beigi,Faramarz Ismail-Beigi,Richard H. Grimm,Jeffrey L. Probstfield,Denise G. Simons-Morton,William T. Friedewald +13 more
TL;DR: In this paper, the authors investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.
Journal ArticleDOI
Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
TL;DR: Although ATP III identified CVD as the primary clinical outcome of the metabolic syndrome, most people with this syndrome have insulin resistance, which confers increased risk for type 2 diabetes, when diabetes becomes clinically apparent, CVD risk rises sharply.
Journal ArticleDOI
C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
TL;DR: The addition of the measurement of C-reactive protein to screening based on lipid levels may provide an improved method of identifying persons at risk for cardiovascular events.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
TL;DR: The reduction associated with the use of aspirin in the risk of a first myocardial infarction appears to be directly related to the level of C-reactive protein, raising the possibility that antiinflammatory agents may have clinical benefits in preventing cardiovascular disease.
Related Papers (5)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Peter Duewell,Hajime Kono,Katey J. Rayner,Katey J. Rayner,Cherilyn M. Sirois,Gregory I. Vladimer,Franz Bauernfeind,George S. Abela,Luigi Franchi,Guillermo Gabriel Nuñez,Max Schnurr,Terje Espevik,Egil Lien,Katherine A. Fitzgerald,Kenneth L. Rock,Kathryn J. Moore,Kathryn J. Moore,Samuel D. Wright,Veit Hornung,Eicke Latz,Eicke Latz +20 more